CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 49 enrolled
Drug / intervention
VC-02 Combination Productcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03163511
NCT03163511Phase 2Completed
CompareCT.gov

An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness

ViaCyte·interventional·Posted May 23, 2017·Updated Dec 3, 2024

In Brief

A Phase 2 clinical trial evaluating VC-02 Combination Product for Type 1 Diabetes Mellitus With Hypoglycemia. Completed, enrolled 49 participants across 10 sites in 3 countries.

Detailed Summary

VC02-101 will evaluate an experimental cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes and Hypoglycemia Unawareness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus With Hypoglycemia
CountriesBelgium, Canada, United States
CollaboratorsCalifornia Institute for Regenerative Medicine (CIRM), Horizon 2020 - European Commission, Vertex Pharmaceuticals Incorporated

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 23, 2017
Enrollment StartJul 6, 2017
Primary CompletionOct 13, 2023
Study CompletionOct 19, 2023
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 9.1 years ago

Interventions

VC-02 Combination Productcombination

PEC-01 cells loaded into a Delivery Device